Edition:
United Kingdom

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

69.61USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$69.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
141,690
52-wk High
$108.62
52-wk Low
$57.51

Chart for

About

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug... (more)

Overall

Beta: --
Market Cap(Mil.): $2,592.25
Shares Outstanding(Mil.): 39.12
Dividend: --
Yield (%): --

Financials

  BPMC.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -3.07 -- --
ROI: -34.88 1.79 14.61
ROE: -40.89 3.28 16.33

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

17 May 2018

CORRECTED-UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO, May 16 An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

17 May 2018

BRIEF-Blueprint Medicines Q1 Loss Per Share $1.29

* BLUEPRINT MEDICINES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

02 May 2018

High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.

03 Apr 2018

Competitors

Earnings vs. Estimates